Current stock page

Financial Data

LLY Financial Data

Revenue · Earnings · Margins · Balance Sheet · Cash Flow

HealthcareDrug Manufacturers - GeneralScore data as of Sep 2, 2026

LLY

Financial Data
Eli Lilly and Company
Healthcare· Drug Manufacturers - General
AIQ Score
NeutralAIQ Edge 3/10
Low Priority
Relative Laggard
Score data as of Sep 2, 2026
Last price
$1,165.59
+$5.59 (+0.48%)
Latest market quote
Momentum23
Value25
Quality76
Risk Resilience45
Sentiment
View financial data

Financial Data Overview

Detailed revenue, earnings, margins, balance sheet, cash flow, valuation metrics, technical indicators, and risk measures for deeper research.

Quarterly periods
8
Fundamental metrics
10
Technical indicators
12
Risk measures
6

Quarterly Financial Statements

Updated Sep 2, 2026.

Income statement
8 periods
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-30
Revenue$22.97B$19.8B$19.29B$17.6B$15.56B$12.73B$13.53B$11.44B
Gross Profit$19.71B$16.22B$16.41B$14.59B$13.11B$10.5B$11.13B$9.27B
Operating Income
Net Income$7.1B$7.4B$6.64B$5.58B$5.66B$2.76B$4.41B$970.3M
EPS$7.95$8.27$7.41$6.22$6.3$3.07$4.91$1.08
Cash flow statement
8 periods
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-30
Operating Cash Flow$10.69B$5.33B$3.22B$8.84B$3.09B$1.67B$2.47B$3.71B
Capital Expenditure-$2.93B-$2.33B-$2.55B-$223.9M-$1.8B-$3.27B-$1.75B-$4.17B
Free Cash Flow$7.76B$3.01B$677.9M$8.61B$1.28B-$1.6B$726.6M-$458.9M
Net Cash Provided By Operating Activities$10.69B$5.33B$3.22B$8.84B$3.09B$1.67B$2.47B$3.71B
Balance sheet
8 periods
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-30
Total Assets$142.28B$116.58B$112.48B$114.94B$100.92B$89.39B$78.71B$75.61B
Total Debt$54.91B$43.37B$0$42.61B$40.07B$38.72B$33.83B$31.3B
Cash And Cash Equivalents
Total Liabilities$108.4B$85.38B$85.94B$91.08B$82.57B$73.54B$64.44B$61.29B
Total Stockholders Equity$33.88B$31.2B$26.54B$23.85B$18.35B$15.85B$14.27B$14.32B
Key financial metrics
8 periods
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-30
P/E ratio37.7227.836.3630.6530.9167.239.28205.67
P/B ratio31.5926.37028.7638.347.0548.8256.06
P/S ratio46.5941.5550.0238.8844.9958.2751.269.78
Debt To Equity1.621.3901.792.182.442.372.19
Free Cash Flow Yield
Financial ratios
8 periods
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-30
P/E ratio
P/B ratio31.5926.37028.7638.347.0548.8256.06
P/S ratio46.5941.5550.0238.8844.9958.2751.269.78
Return On Equity20.94%23.71%0.00%23.46%30.98%17.50%31.07%6.81%
Debt To Equity

Current Stock Metrics

Current fundamental, technical, and risk readings in one place.

Fundamental metrics
Pe
40.69
multipleSep 1, 2026
Pb
32
multipleSep 1, 2026
Revenue Growth Yoy
16.04
percentSep 1, 2026
EPS Growth Yoy
-3.87
percentSep 1, 2026
Gross Margin
84.01
percentSep 1, 2026
Operating Margin
43.92
percentSep 1, 2026
ROE
92.58
percentSep 1, 2026
ROIC
27.38
percentSep 1, 2026
Debt To Equity
1.62
ratioSep 1, 2026
FCF Yield
1.75
percentSep 1, 2026
Technical indicators
Close
1,165.59
priceSep 2, 2026
Volume
2,522,522
volumeSep 1, 2026
Rsi14
39.58
indexSep 1, 2026
MACD
-0.59
indexSep 1, 2026
MACD Signal
9.23
indexSep 1, 2026
MACD Histogram
-9.82
indexSep 1, 2026
Adx14
16.36
indexSep 1, 2026
Sma50
1,189.16
priceSep 1, 2026
Sma200
1,061.33
priceSep 1, 2026
Atr14
37.26
priceSep 1, 2026
Historical Volatility
0.38
percentSep 1, 2026
Volume Ma20
2,780,004.25
volumeSep 1, 2026
Risk measures
Resilience Score
45
score_0_100Sep 1, 2026
Beta
0.51
ratioSep 1, 2026
Volatility Annual
35.89
percentSep 1, 2026
Max Drawdown
-23.31
percentSep 1, 2026
Sharpe Ratio
1.35
ratioSep 1, 2026
Var95
-2.67
percentSep 1, 2026

Detailed Metrics

Additional measures remain available here while the decision pages stay focused.

Additional fundamental metrics

No additional fundamental metrics are available.

Additional technical indicators

No additional technical indicators are available.

Additional risk measures

No additional risk measures are available.

LLY Financial Data FAQ

What is Eli Lilly and Company's revenue?

Eli Lilly and Company's revenue is one of the core financial data points for LLY. Use it with revenue growth, margins, and EPS to understand whether sales are translating into earnings power.

Is Eli Lilly and Company's revenue growing?

Revenue growth shows whether Eli Lilly and Company is expanding from prior periods. Compare growth with margins and free cash flow because faster sales growth is more valuable when profitability holds up.

What is LLY's EPS?

LLY's EPS, or earnings per share, helps connect net income to each share. EPS should be compared with EPS growth, P/E ratio, and analyst expectations.

What is Eli Lilly and Company's net income?

Eli Lilly and Company's net income shows profit after costs, taxes, and other expenses. It should be read with revenue, operating margin, EPS, and free cash flow.

How much free cash flow does Eli Lilly and Company generate?

Free cash flow shows how much cash Eli Lilly and Company generates after capital spending. It is useful for judging reinvestment capacity, buybacks, debt reduction, and valuation support.

How much cash and debt does Eli Lilly and Company have?

Cash and debt help frame LLY's balance-sheet flexibility. Compare liquidity and leverage with free cash flow and profitability before judging financial strength.